Novo Nordisks long-acting amylin analog cagrilintide reduced body weight by 11.8% after 68 weeks of treatment, according to a sub-analysis of a late-stage trial evaluating the drug
Seven additional phase 3 readouts are expected throughout this year, covering a range of conditions including type 2 diabetes, obstructive sleep apnea, chronic low back pain, cardiovascular outcomes, and metabolic dysfunction-associated steatotic liver disease
2019, doi: 10.3389/fendo.2019.00376
Ready to invest in a healthier, more confident you
I am delighted with the results of my treatment I feel my skin looks so much fresher and this in turn has lifted my self esteem which had previously been at a low point
If you want to learn how tirzepatide fits into a broader treatment plan, this tirzepatide weight loss guide explains the steps in more detail